Meju Forecast to Turn Profitable on M350, Dong-A ST Tie-Up

Meju Profit Turnaround Outlook Hinges on Earnings Delivery

For investors assessing Meju, the focus now should be not on the scale of its medical-device narrative but on how quickly revenue converts into profit. A Hana Securities forecast reported by Infostock Daily on the 28th projects that Meju will turn profitable for the full year, citing its M350 vital-sign monitoring patch and sales partnership with Dong-A ST. The analysis suggests that product development and the sales network could translate into actual earnings, but no investment rating or target price was provided.

The M350 is a device designed to continuously monitor vital signs previously measured using multiple pieces of equipment through a single ultra-compact patch. Hana Securities analyst Park Chan-sol said Meju has achieved product competitiveness by enabling the M350 to measure five core vital signs. The approvals confirmed in the article cover electrocardiogram and oxygen saturation monitoring; the timing and regulatory approval of a blood-pressure monitoring feature have not yet been finalized.

How the M350 Could Feed Through to Meju’s Earnings

The link between this development and earnings lies in combining the product with sales capabilities. While validation and sales are taking place simultaneously at leading Korean hospitals, the sales partnership with Dong-A ST has been presented as a way to expand customer access. If the M350’s integrated functionality supports hospitals’ adoption decisions and the partnership generates sales, its technical differentiation could translate into revenue.

Hana Securities forecast Meju’s full-year revenue at 19 billion won, up 157.5% year over year. The same forecast projected full-year operating profit of 4 billion won and an operating margin of 21%. The central point of the analysis is that it anticipates not only top-line expansion but also a return to profitability. Because actual revenue and operating profit have not yet been reported, investors should distinguish forecasts from confirmed earnings.

600,000 Beds Versus 50,000: Reading an Early-Stage Market

Analyst Park Chan-sol estimated that fewer than 50,000 of South Korea’s roughly 600,000 hospital beds currently use wearable devices. These figures indicate an early-stage market with many beds yet to adopt the technology, rather than demand already secured. This may provide room for Meju to expand, but low penetration does not automatically guarantee higher sales.

If validation leads to sales and the existing sales trajectory continues, confidence in this year’s earnings forecast would strengthen. Conversely, if hospital adoption remains at the validation stage or the blood-pressure monitoring feature is delayed, the assessment based on the M350’s integrated monitoring capabilities could weaken. As the hospitals and their number have not been disclosed, the current information is insufficient to calculate the scope or pace of adoption.

Implications for Meju and Dong-A ST

• Meju: If Hana Securities’ forecast of 19 billion won in full-year revenue and 4 billion won in operating profit materializes, it would demonstrate that the M350 and sales partnership are contributing to improved earnings. Meju’s current market capitalization of 136 billion won was also described as attractive, but the absence of a target price limits the assumptions and scope of that valuation assessment.
• Dong-A ST: The relationship confirmed in the article is a sales partnership with Meju. While the partnership’s role in supporting Meju’s sales expansion is positive, no amount or proportion of the impact on Dong-A ST’s own earnings was provided.
• Wearable medical devices: Regulatory approvals for electrocardiogram and oxygen saturation monitoring, together with hospital validation and sales, illustrate the commercialization process for vital-sign monitoring patches. However, without product and earnings data for competitors, there is insufficient evidence to determine the extent of benefits across the industry sector or any company’s relative advantage.

Next Checks: Approvals, Sales and Earnings

Investors should first verify whether the blood-pressure monitoring feature is added and receives regulatory approval. The next questions are whether validation underway at leading Korean hospitals translates into higher sales and how much the Dong-A ST sales partnership contributes to revenue. The final test will be Meju’s actual full-year revenue and operating profit.

The bullish scenario is that hospital sales continue and full-year earnings meet Hana Securities’ forecast. Thereafter, whether next year’s revenue exceeds the 28.5 billion won guidance issued at the time of listing will determine the sustainability of growth. Overseas expansion was mentioned only as a possibility, with no specific schedule or results confirmed. What is currently visible is the link among technology, sales and the earnings outlook; upcoming disclosures and earnings releases will show whether that link is translating into reality.

This article was automatically summarized and analyzed based on the original news report. View Original Article (Infostock Daily)